Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.
Boston Code-a-Thon Team Triangle: Claus C Becker, Greg Borenstein, Johnny Hujol, Daniel Karlin, Greg Kust, Francis Yee Pro...
Executive Summary <ul><li>Self-selected to work together on device-based health-assessment problem </li></ul><ul><li>Focus...
Overview of Movement Disorders <ul><li>Many diseases impact movement.  We chose to focus on pure movement disorders (MDs) ...
Current Gaps <ul><li>Problem </li></ul><ul><li>Current practice does an inadequate job of standardized assessment of MD an...
Our Approach: automate Abnormal Involuntary Movement Scale <ul><li>We built a Processing application that uses PrimeSense’...
Impact on Health <ul><li>Customized care </li></ul><ul><ul><li>Clinical effectiveness & dose modification </li></ul></ul><...
How TTAS might be used <ul><li>At home or in the doctors office </li></ul><ul><li>Before and after taking medication to es...
Issues we wrestled with <ul><li>Optimizing distance to and interaction with the Kinect </li></ul><ul><li>Defining  normal ...
Next steps <ul><li>Refine software to include directions (e.g. ‘raise arms higher’) </li></ul><ul><li>Expand TTAS to entir...
References February 19, 2011 Copyright 2011: Team Triangle http://www.neurologychannel.com/movementdisorders/overview-of-m...
Prochain SlideShare
Chargement dans…5
×

Kinect Abnormal Movement Assessment System Presentation at Health 2.0 Boston

3 270 vues

Publié le

Presentation given at the end of the Boston Health 2.0 hackday on 2/19/11 demonstrating and explaining the system we built that day for assessing involuntary movement as part of psychiatric patient tracking.

  • Identifiez-vous pour voir les commentaires

Kinect Abnormal Movement Assessment System Presentation at Health 2.0 Boston

  1. 1. Boston Code-a-Thon Team Triangle: Claus C Becker, Greg Borenstein, Johnny Hujol, Daniel Karlin, Greg Kust, Francis Yee Project Triangle: Proof of Concept Using Kinect for Assessment of Tremor in People with Movement Disorders February 19, 2011 Copyright 2011: Team Triangle
  2. 2. Executive Summary <ul><li>Self-selected to work together on device-based health-assessment problem </li></ul><ul><li>Focused on disease where diagnosis and evaluation is movement based </li></ul><ul><li>Developed Kinect-based application to enhance clinical assessment using home-grown and open-source code </li></ul><ul><li>Suggest scorecard report for physicians </li></ul>February 19, 2011 Copyright 2011: Team Triangle
  3. 3. Overview of Movement Disorders <ul><li>Many diseases impact movement. We chose to focus on pure movement disorders (MDs) </li></ul><ul><li>MDs are neurological conditions that effect the speed, fluency, and ease of movement; and the ability to stop movement </li></ul><ul><li>Different kinds of MDs </li></ul><ul><ul><li>Dyskinesia: abnormal fluency or speed of movement (tardive dyskinesia) </li></ul></ul><ul><ul><li>Hyperkinesia: excessive or involuntary movement (huntington chorea) </li></ul></ul><ul><ul><li>Hypokinesia: slowed or absent voluntary movement </li></ul></ul>February 19, 2011 Copyright 2011: Team Triangle Our approach will complement clinical practices for the three types of MDs
  4. 4. Current Gaps <ul><li>Problem </li></ul><ul><li>Current practice does an inadequate job of standardized assessment of MD and the frequency of the evaluations is too low. There is interest in daily (morning & night) tracking. A simple, at home data capture device may help to assess: </li></ul><ul><ul><li>Disease progression, on a more granular & temporal basis </li></ul></ul><ul><ul><li>Response to therapy (e.g. efficacy, dosing, adverse events) </li></ul></ul><ul><ul><li>Adherence to therapy </li></ul></ul><ul><li>Needs </li></ul><ul><ul><li>Adherent & non-adherent progression measures </li></ul></ul><ul><ul><li>Utilize Kinect device to measure range of movements </li></ul></ul><ul><ul><li>Provide clinicians with more meaningful patient movement samples </li></ul></ul>February 19, 2011 Copyright 2011: Team Triangle
  5. 5. Our Approach: automate Abnormal Involuntary Movement Scale <ul><li>We built a Processing application that uses PrimeSense’s OpenNI middleware and the OSCeleton library for the Kinect to capture joint position data from the user </li></ul><ul><li>Our application tracks movement of the knee and hands over a ten second period and then displays user score based on the quantity of involuntary motion detected </li></ul><ul><li>https://github.com/atduskgreg/Triangle-Tremor-Assessment-Test </li></ul>February 19, 2011 Copyright 2011: Team Triangle
  6. 6. Impact on Health <ul><li>Customized care </li></ul><ul><ul><li>Clinical effectiveness & dose modification </li></ul></ul><ul><ul><li>Engaged patient participation </li></ul></ul><ul><ul><li>Adherence measures </li></ul></ul><ul><ul><ul><li>e.g. prescription status (medication possession ratio [MPR]) </li></ul></ul></ul><ul><li>Clinical scorecard: Severity score compared to baseline </li></ul><ul><ul><li>MPR* + Patient self report + TTAS** = Health Score </li></ul></ul><ul><li>Other applications </li></ul><ul><ul><li>Tardive dyskinesia, Parkinson’s, Huntington’s </li></ul></ul><ul><ul><li>Movement disorders associated with drug side effects </li></ul></ul>February 19, 2011 Copyright 2011: Team Triangle **TTAS: Triange tremor assessment score; *MPR: Medicine possession ratio
  7. 7. How TTAS might be used <ul><li>At home or in the doctors office </li></ul><ul><li>Before and after taking medication to estimate effect </li></ul><ul><li>Daily to track progress (many data points to overcome noise) </li></ul>February 19, 2011 Copyright 2011: Team Triangle
  8. 8. Issues we wrestled with <ul><li>Optimizing distance to and interaction with the Kinect </li></ul><ul><li>Defining normal level of involuntary movement </li></ul><ul><li>Software limitations in initializing device </li></ul><ul><li>Regulatory approval issues – device results not sufficiently validated for use in clinical treatments </li></ul>February 19, 2011 Copyright 2011: Team Triangle
  9. 9. Next steps <ul><li>Refine software to include directions (e.g. ‘raise arms higher’) </li></ul><ul><li>Expand TTAS to entire AIMS scale </li></ul><ul><li>Improve statistical treatment of data </li></ul><ul><li>Clinical base-line and validation </li></ul>February 19, 2011 Copyright 2011: Team Triangle
  10. 10. References February 19, 2011 Copyright 2011: Team Triangle http://www.neurologychannel.com/movementdisorders/overview-of-movement-disorders.shtml http://www.nlm.nih.gov/medlineplus/movementdisorders.html http://www.atlantapsychiatry.com/forms/AIMS.pdf

×